YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
The YAP-HER3 axis is crucial for the survival and adaptive resistance of high YAP-expressing RET-aberrant cancer cells treated with RET-TKIs. Combining YAP/HER3 inhibition with RET-TKIs represents a highly potent strategy for initial treatment. See related commentary by Ortiz-Cuaran and Leonce, p. 958.
Authors
- Koji Date (ORCID: https://orcid.org/0000-0002-1283-4083)
- Soichi Hirai (ORCID: https://orcid.org/0000-0002-2537-6499)
- Satoshi Watanabe (ORCID: https://orcid.org/0000-0003-0041-6981)
- Toshiyuki Sakai (ORCID: https://orcid.org/0000-0002-7865-2258)
- Yasuhiro Gotô (ORCID: https://orcid.org/0000-0003-2235-8567)
- Yasuhito Fujisaka (ORCID: https://orcid.org/0000-0002-9175-3627)
- Akihiro Tamiya (ORCID: https://orcid.org/0000-0003-3599-2583)
- Seiji Yano (ORCID: https://orcid.org/0000-0002-6151-2988)
- Michiko Tsuchiya (ORCID: https://orcid.org/0009-0006-9699-4039)
- Yoshihiko Sakata (ORCID: https://orcid.org/0000-0002-3300-9138)
- Mano Horinaka (ORCID: https://orcid.org/0000-0001-8168-1802)
- Kazumi Nishino (ORCID: https://orcid.org/0000-0003-2000-7472)
- Koichi Takayama (ORCID: https://orcid.org/0000-0002-7723-8960)
- Satoshi Muto (ORCID: https://orcid.org/0000-0002-9511-5593)
- Keiko Tanimura (ORCID: https://orcid.org/0000-0002-7826-4466)
- Hisanori Uehara (ORCID: https://orcid.org/0000-0003-1709-1386)
- Yuki Katayama (ORCID: https://orcid.org/0000-0001-9209-4267)
- Go Saito (ORCID: https://orcid.org/0000-0002-7875-6399)
- Yohei Matsui (ORCID: https://orcid.org/0000-0001-7850-5330)
- Takayuki Takeda (ORCID: https://orcid.org/0000-0002-8375-6940)
- Hayato Kawachi (ORCID: https://orcid.org/0000-0002-1673-2260)
- Ryota Nakamura (ORCID: https://orcid.org/0000-0001-9519-2276)
- Naoki Furuya (ORCID: https://orcid.org/0000-0001-7162-5946)
- Shinsaku Tokuda (ORCID: https://orcid.org/0000-0002-3726-7775)
- Kenji Morimoto (ORCID: https://orcid.org/0000-0003-3394-1838)
- Daichi Fujimoto (ORCID: https://orcid.org/0000-0003-0615-3000)
- Masaki Ishida (ORCID: https://orcid.org/0000-0002-1890-7378)
- Tadaaki Yamada (ORCID: https://orcid.org/0000-0002-6945-281X)
- Sachiko Arai
Institutions
- Kanazawa University (JP)
- Fukushima Medical University (JP)
- Hyogo Medical University (JP)
- Fujita Health University (JP)
- Chiba University (JP)
- St. Marianna University School of Medicine (JP)
- Osaka Medical and Pharmaceutical University (JP)
- Kyoto Prefectural University of Medicine (JP)
- Kanazawa Medical Center (JP)
- Saiseikai Kumamoto Hospital (JP)
- Rakuwakai Otowa Hospital (JP)
- Kyoto College of Medical Science (JP)
- Osaka International Cancer Institute (JP)
- Life Science Institute (JP)
- Tokushima University Hospital (JP)
- Niigata University Medical and Dental Hospital (JP)
- Fujita Health University Hospital (JP)
- Nantan General Hospital (JP)
- Osaka International Cancer Institute (JP)
- Japanese Red Cross Society Kyoto Daini Hospital (JP)
- NHO Kinki Chuo Chest Medical Center (JP)
- Niigata University (JP)
- Osaka University of Pharmaceutical Sciences (JP)
- Tokushima University (JP)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-1762
- Citations
- 5
- Primary Topic
- Cancer-related gene regulation
- Type
- article
- Field-Weighted Citation Impact
- 1.17
Funders
- Kanazawa University
- Princess Takamatsu Cancer Research Fund